Can a new injection tame relapsing MS?
NCT ID NCT07749157
First seen Aug 06, 2026 · Last updated Aug 07, 2026 · Updated 1 time
Summary
This early-stage trial is testing an investigational drug called RO7845860, given as an injection under the skin, in people with relapsing multiple sclerosis (MS). The main goals are to check the drug's safety, how the body handles it, and its effects on immune cells. The study will include around 85 participants and involves multiple dose levels to find a safe and tolerable approach.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- RO7845860, an investigational drug given as an injection under the skin
- What this could lead to
- If successful, this could lead to a new treatment option that helps control relapsing multiple sclerosis by targeting certain immune cells.
- What could go wrong
- This is an early, small study focused on safety and dosing, so it may not lead to an approved treatment. Possible side effects and the drug's effectiveness are not yet known.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSING MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple injection replace an IV for MS treatment?
- Timing of MS drug may change disease course
- MS patients switch drugs to save immune defenses
- Real-World study tracks why MS patients switch to kesimpta
- MS patients may soon get a simpler shot option
- MS drug delivery showdown: belly vs. thigh, pen vs. syringe